title: Philadelphia chromosome-negative chronic myeloid leukaemia: a report of 14 new cases.
abstract: The Philadelphia chromosome (Ph) is the cytogenetic hallmark of chronic myeloid leukaemia (CML) and is used to confirm the diagnosis of CML based on clinical and morphological criteria. We investigated 14 patients with features of CML but without detectable Ph chromosome. In seven patients, referred to as BCR+, M-bcr/abl rearrangement was detected by polymerase chain reaction (PCR). The seven remaining patients did not have M-bcr/abl rearrangement and are described as BCR-. BCR- patients were younger, had lower white blood cell counts (WBC) and lower basophilia. Four BCR- and four BCR+ patients underwent blastic transformation (BT). Response to therapy was fairly similar in both populations. According to French-American-British (FAB) Cooperative Leukaemia Group guidelines, all BCR- patients were classified as having classic form CML or 'chronic granulocytic leukaemia' (CGL) when based only on morphological data. This study further confirms the existence of true CML cases without Ph chromosome or M-bcr/abl rearrangement and shows that this entity differs only slightly from classic form Ph+ CML. The Ph-BCR- subgroup raises two problems. First, the differential diagnosis with atypical CML or CMML, based on morphological data, and secondly, the therapeutic follow-up in the absence of a specific marker. In contrast, the residual disease of Ph-BCR- patients can be monitored by PCR. More advanced molecular and biochemical techniques will be required to understand which molecular mechanisms underlie Ph-BCR- CML, resulting in phenotypes sometimes indistinguishable from Ph+ CML.
authors.affiliation: Haematology Department, Centre Anti-Cancéreux de Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Costello
authors.forename: M
authors.initials: M
authors.lastname: Lafage
authors.forename: Y
authors.initials: Y
authors.lastname: Toiron
authors.forename: V
authors.initials: V
authors.lastname: Brunel
authors.forename: D
authors.initials: D
authors.lastname: Sainty
authors.forename: C
authors.initials: C
authors.lastname: Arnoulet
authors.forename: M J
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
mesh_terms: D001483:Base Sequence; D015139:Blotting, Southern; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010677:Philadelphia Chromosome; D016896:Treatment Outcome